School of Sciences, Shanghai Institute of Technology, Shanghai 201418, China.
Key Laboratory of Systems Biology, State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
Biomed Res Int. 2020 Nov 14;2020:8579651. doi: 10.1155/2020/8579651. eCollection 2020.
Many studies have found that long noncoding RNAs (lncRNAs) are differentially expressed in hepatocellular carcinoma (HCC) and closely associated with the occurrence and prognosis of HCC. Since patients with HCC are usually diagnosed in late stages, more effective biomarkers for early diagnosis and prognostic prediction are in urgent need.
The RNA-seq data of liver hepatocellular carcinoma (LIHC) were downloaded from The Cancer Genome Atlas (TCGA). Differentially expressed lncRNAs and mRNAs were obtained using the edgeR package. The single-sample networks of the 371 tumor samples were constructed to identify the candidate lncRNA biomarkers. Univariate Cox regression analysis was performed to further select the potential lncRNA biomarkers. By multivariate Cox regression analysis, a 3-lncRNA-based risk score model was established on the training set. Then, the survival prediction ability of the 3-lncRNA-based risk score model was evaluated on the testing set and the entire set. Function enrichment analyses were performed using Metascape.
Three lncRNAs (RP11-150O12.3, RP11-187E13.1, and RP13-143G15.4) were identified as the potential lncRNA biomarkers for LIHC. The 3-lncRNA-based risk model had a good survival prediction ability for the patients with LIHC. Multivariate Cox regression analysis proved that the 3-lncRNA-based risk score was an independent predictor for the survival prediction of patients with LIHC. Function enrichment analysis indicated that the three lncRNAs may be associated with LIHC via their involvement in many known cancer-associated biological functions.
This study could provide novel insights to identify lncRNA biomarkers for LIHC at a molecular network level.
许多研究发现长非编码 RNA(lncRNA)在肝细胞癌(HCC)中表达差异,与 HCC 的发生和预后密切相关。由于 HCC 患者通常在晚期被诊断,因此更需要有效的生物标志物用于早期诊断和预后预测。
从癌症基因组图谱(TCGA)下载肝肝细胞癌(LIHC)的 RNA-seq 数据。使用 edgeR 包获得差异表达的 lncRNA 和 mRNA。构建 371 个肿瘤样本的单样本网络,以识别候选 lncRNA 生物标志物。进行单变量 Cox 回归分析,进一步选择潜在的 lncRNA 生物标志物。通过多变量 Cox 回归分析,在训练集上建立基于 3 个 lncRNA 的风险评分模型。然后,在测试集和整个数据集上评估基于 3 个 lncRNA 的风险评分模型的生存预测能力。使用 Metascape 进行功能富集分析。
鉴定出 3 个 lncRNA(RP11-150O12.3、RP11-187E13.1 和 RP13-143G15.4)作为 LIHC 的潜在 lncRNA 生物标志物。基于 3 个 lncRNA 的风险模型对 LIHC 患者具有良好的生存预测能力。多变量 Cox 回归分析证实,基于 3 个 lncRNA 的风险评分是 LIHC 患者生存预测的独立预测因子。功能富集分析表明,这三个 lncRNA 可能通过参与许多已知的癌症相关生物学功能与 LIHC 相关。
本研究可以在分子网络水平上为识别 LIHC 的 lncRNA 生物标志物提供新的见解。